Viveo 4Q net loss R$78.3M

Viveo 4Q net loss R$78.3M

Viveo Inc. reported a net loss of R$78.3 million for the fourth quarter ended December 31, 2025, according to its latest financial disclosure. This marks a significant shift from its net income of R$12.4 million in the same period in 2024. The loss reflects a combination of declining revenue in key business segments and increased operational expenditures. Total revenue for the quarter fell 14% year-over-year to R$410 million, driven by reduced demand in its core healthcare technology division and higher-than-anticipated R&D costs.

The company attributed the financial performance to macroeconomic headwinds, including inflationary pressures and regulatory changes impacting its international operations. Viveo also noted a R$22.1 million non-cash impairment charge related to underperforming assets in its digital therapeutics portfolio.

Analysts highlight that the loss underscores broader challenges in the healthcare tech sector, where margin compression and delayed product launches have affected multiple firms. Viveo's board has announced a strategic review of its cost structure and capital allocation priorities, with plans to release a revised business outlook in early Q2 2026. Investors are advised to monitor the company's cash reserves, which remain stable at R$315 million as of December 2025.

No material litigation or dividend adjustments were disclosed alongside the report.